Saturday, August 19, 2017

Novartis Phase 3 cancer drug Panobinostat may correct Niemann Pick Type C cholesterol defect through inhibiting histone deacetylase (HDAC)

March 21, 2011 by  
Filed under Featured Stories

I almost fell off my chair a few minutes ago. I just posted a blog on news from Notre Dame and Cornell about HDAC inhibitors correcting the Niemann Pick Type C defect in cell culture. I just read on PNAS that the Novartis cancer drug Panobinostat (LBH-589), a Phase 3 drug developed for the treatment [...]

Share this:
  • Print
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • Diigo
  • email
  • PDF
  • Twitter
  • Yahoo! Bookmarks

FDA Approves Request For New Cyclodextrin Treatment For Niemann Pick Type C

September 25, 2010 by  
Filed under Cyclodextrin, Featured Content

FDA Approval Received! Children’s Hospital Oakland Receives FDA Clearance to Begin World’s First Cyclodextrin Administration Into the Brains of Twins with Rare and Deadly Cholesterol Disease Sugar Molecule Used In Common Food and Household Products Like Febreze® Fabric Refresher Called Hydroxypropyl Beta Cyclodextrin (HPßCD) Will be Delivered into Twins’ Central Nervous System in an Attempt [...]

Share this:
  • Print
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • Diigo
  • email
  • PDF
  • Twitter
  • Yahoo! Bookmarks